Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NC-531 (Neurochem).

Hugo Geerts1

  • 1In Silico Biosciences, 686 Westwind Drive, Berwyn, PA 19312, USA. Hugo-Geerts@in-Silico-Biosciences.com

Current Opinion in Investigational Drugs (London, England : 2000)
|February 27, 2004
PubMed
Summary
This summary is machine-generated.

NC-531, a novel drug candidate, shows promise in inhibiting amyloid plaque formation, a key factor in Alzheimer's disease. Clinical trials are progressing to evaluate its potential as a therapeutic agent.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology study.

Frontiers in pharmacology·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Interactions of Therapeutic Antibodies With Presynaptically-Released Misfolded Proteins in Neurodegenerative Diseases. A Spatial Monte-Carlo Simulation Study.

CPT: pharmacometrics & systems pharmacology·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Alzheimer's disease is characterized by amyloid plaque formation.
  • Developing effective treatments for Alzheimer's disease remains a significant challenge.

Purpose of the Study:

  • To evaluate NC-531 as a potential therapeutic agent for Alzheimer's disease.
  • To assess the safety and efficacy of NC-531 through clinical trials.

Main Methods:

  • NC-531 is a sulfated glycosaminoglycan mimetic.
  • Clinical trials (Phase I and Phase II) were conducted to assess NC-531.

Main Results:

  • NC-531 demonstrated the ability to inhibit amyloid plaque formation.
  • Clinical trials for NC-531 were in progress between 1999 and 2002.

Conclusions:

  • NC-531 holds potential for the treatment of Alzheimer's disease.
  • Further clinical development is warranted to confirm efficacy and safety.